Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2154
Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Ligand-directed targeting and molecular imaging based on vascular zip codes revealed by in vivo phage display
2nd World Congress on Bio Summit & Molecular Biology Expo
Renata Pasqualini
University of New Mexico Health Sciences Center, USA
Keynote: J Biotechnol Biomater
Abstract
We have developed in vivo phage display, a functional peptide and antibody screening established in animal models and later in patients, to isolate homing ligands and enable subsequent identification of tissue-specific receptors. Systematic implementation of this strategy advanced the construction of a comprehensive map of vascular markers in each organ, tissue or disease. Indeed, our pioneering discoveries of tissue-specific and angiogenesis-related receptors (vascular "ZIP codes") may lead to a new ligand-directed pharmacology. Over the last few years our efforts have been focused on characterizing the vascular diversity associated with individual cancer patients using antibody-based drug discovery in a precision medicine context and optimizing targeted nanoparticles for drug delivery without off-target toxicity. These new programs represent fertile ground for discovery and drug development.Biography
Renata Pasqualini is the Professor of Medicine and Cancer Experimental Therapeutics, Associate Director for Translational Research and Chief of the Division of Molecular Medicine at the University of New Mexico Comprehensive Cancer Center. She has received her PhD from the Ludwig Institute for Cancer Research and did Postdoctoral training at Harvard Medical School and at the Burnham Institute in La Jolla, CA. In addition to her activities as the Principal Investigator and Head of a large research laboratory, first at the University of Texas MD Anderson Cancer Center and presently at the University of New Mexico Health Sciences Center, she serves as a Board Member, Reviewer and Chair in multiple review panels for the National Institutes of Health, the Department of Defense, the Department of Energy along with several other American, Asian and European Foundations that support basic and clinical research. She is a Referee for several top journals featuring cutting edge research and technology and has published over 200 papers.
Email: rpasqual@salud.unm.edu
